ClinicalTrials.gg
RecruitingNCT07111078Updated Nov 12, 2026

Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults

A Phase 1 interventional study of VRC-FLUMOS0122-00-VP and ALFQ in Influenza Prevention and Pandemic Influenza Prevention, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Nov 12, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) — 11 open to participants now, 12 under way, none of them phase 3. Influenza, Human · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
101st of 166
56 · median 83
Started
2025
with 4 others
Phase 1
77 of 186
5 open now
Primary completion
2027-08
later than 7 of 10 live
Registered
183rd of 186
by date

Among the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 101st largest by planned enrollment of the 166 interventional ones that give a count, is one of 5 that started in 2025, is one of 77 in phase 1, reaches primary completion later than 7 of the 10 other live ones, and was the 183rd registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

11 of the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu. Some vaccines are combined with adjuvants. Adjuvants are special salts or fats that help vaccines work better. Researchers are looking for ways to make flu vaccines more effective.

Objective:

To test a new flu vaccine with and without a new adjuvant.

Eligibility:

Healthy adults aged 18 to 50. They must have had at least 1 flu vaccine since 2020.

Design:

Participants will have 12 clinic visits over 15 months.

The vaccine is given as an injection into the muscle of the upper arm. Participants will be vaccinated during 2 visits spaced 4 months apart. Half will receive just the vaccine; half will receive the vaccine plus the adjuvant. They will be monitored for at least 30 minutes after each shot.

Participants will keep a diary for 7 days after each shot. They check their temperature every day and record any symptoms.

Participants will have 10 follow-up clinic visits plus 4 phone calls. They will have 4 to 10 tablespoons of blood drawn at each clinic visit. Fluid samples will be collected from their nose and mouth. They will be checked for any health changes.

Participants may opt to undergo apheresis: Blood will be taken from the body through a needle inserted into a vein. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be returned to the body through a different needle.

Read the detailed description

Design:

This is a phase I, open-label, dose escalation study to evaluate the safety, tolerability, and immunogenicity of the stem quadrivalent influenza vaccine VRC-FLUMOS0122-00-VP (SteMos1) with and without Army Liposome Formulation containing saponin QS-21 (ALFQ) adjuvant. The hypotheses are that the SteMos1 vaccine is safe and tolerable when administered alone or with ALFQ adjuvant, that this vaccine elicits vaccine specific immune responses, and that addition of the ALFQ adjuvant increases the magnitude and breadth of the elicited immune responses. The primary objective is to evaluate the safety and tolerability of the investigational vaccine with and without ALFQ adjuvant in healthy adults. Secondary objectives are related to the immunogenicity of the investigational vaccine with and without ALFQ adjuvant.

Study Products:

The investigational vaccine, SteMos1, was developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID). The adjuvant, Army Liposome Formulation containing QS-21 (ALFQ), was developed and provided by the Walter Reed Army Institute of Research (WRAIR).

The SteMos1 vaccine includes stabilized HA stems from the following 4 influenza strains:

Influenza A:

Group 1:

H2: A/Singapore/1/1957

H5: A/lndonesia/5/2005

Group 2:

H7: A/Anhui/1/2013

H10: A/Jiangxi-Donghu/346/2013

FLUMOS0122-00-VP (SteMos1) is a sterile, aqueous buffered solution supplied in 3 mL single-dose glass vials containing 0.7 +/- 0.1 mL with a vaccine concentration of 1080 mcg/mL.

The ALFQ drug product is a sterile suspension that contains 240 mcg of monophosphoryl 3-deacyl Lipid A (3D-PHAD) and 120 mcg QS-21 that is vialed at 0.6 mL/vial in 3.0 mL glass vials. 0.5 mL of ALFQ adjuvant will be mixed with the 60 or 180 mcg dose of SteMos1 during preparation in the pharmacy prior to vaccination.

SteMos1 with and without ALFQ adjuvant will be administered intramuscularly (IM) in the deltoid muscle via needle and syringe.

Participants:

Healthy adults 18-50 years of age, inclusive, will be enrolled

Study Plan:

There will be multiple interim safety reviews in this trial. The first review will assess the safety data for Group 1 (60 mcg of SteMos1 alone). Enrollment for Group 1 will be limited to one participant per day for the first three participants. After the third participant's two-week post-vaccination visit, a safety review will determine whether to continue enrollment at the same dose level in Group 1 and to proceed with enrollment of the next dose level, Group 2 (180 mcg of SteMos1 alone), and Group 3 (60 mcg of SteMos1 with ALFQ adjuvant). Group 2 and Group 3 will also enroll one participant per day for the first three participants in each group. Following the two-week post-vaccination visit of the third participant in each group, a safety review will determine whether to continue enrollment at the same dose level in Group 2 and Group 3 and to proceed to the next dose level, Group 4 (180 mcg of SteMos1 with ALFQ adjuvant). At this stage, these interim safety reviews for Group 2 and Group 3 can be conducted simultaneously or at different times, depending on which group first completes enrollment of the initial three participants.

Group 4 will enroll one participant per day for the first three participants. After the two-week post-vaccination visit of the third participant, a final safety review will determine whether to continue enrollment at the same dose level in Group 4. The study will not enroll any participants in Group 5 until available interim safety data from Group 3 and Group 4 are evaluated to select the dose for Group 5.

Once all groups are open, participants will be enrolled at the discretion of the Principal Investigator (PI) to balance enrollments in each group. If a current participant is discontinued from the protocol, a new participant may be enrolled at the discretion of the PI to collect required safety or immunogenicity data.

Solicited reactogenicity will be evaluated using a 7-day diary card. Assessment of vaccine safety will include clinical observation and monitoring of hematological and chemical parameters at clinical visits throughout the study.

Study Duration:

Participants will be followed for safety for a total time of 68 weeks, including through the 2025-2026 influenza season. This safety follow-up includes 52 weeks after the second dose of vaccine.

03

Conditions studied

  • Influenza Prevention
  • Pandemic Influenza Prevention

Browse trials for

Keywords

  • Dose-Escalation
  • INFLUENZA VIRUS
  • Immune Response
  • Respiratory Illness
  • Experimental Vaccine
  • Safety
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A participant must meet all of the following criteria:

  • Healthy adults between the ages of 18-50 years, inclusive
  • Based on history and physical examination, be in good general health and without a history of any of the conditions listed in the exclusion criteria
  • Received at least one licensed influenza vaccine within the 5 years prior to enrollment
  • Able and willing to complete the process
  • The ability to read and comprehend English as all consent and recruitment materials are in English.
  • Available for clinic visits for 68 weeks after the first dose
  • Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process
  • Physical examination and laboratory results without findings and a (BMI) \<= 35 within the 56 days before enrollment
  • Agrees to not receive any licensed influenza vaccination during study participation due to potential confounding of study results
  • Willing to have blood and mucosal samples collected, stored indefinitely, and used for research purposes.

Laboratory Criteria within 56 days before enrollment:

  • WBC and differential within institutional normal range or accompanied by approval of the site Principal Investigator (PI) or designee
  • Total lymphocyte count >= 800 cells/microliter
  • = 125,000-400,000 cells/mircoliter
  • within institutional normal range or accompanied by approval of the PI or designee
  • (ALT) \<= 1.25 x institutional (ULN)
  • Aspartate aminotransferase (AST) \<= 1.25 x institutional ULN
  • Alkaline phosphatase (ALP) \< 1.1 x institutional ULN
  • Total within institutional normal range or accompanied by approval of the PI or designee
  • Serum creatinine \<= 1.1 x institutional ULN
  • Negative for infection by an FDA-approved method of detection

Criteria applicable to women of :

  • Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or serum) on the day of enrollment
  • Agrees to use an effective means of from at least 21 days prior to enrollment through the end of the study

Exclusion criteria

EXCLUSION CRITERIA:

Participant will be excluded if one or more of the following conditions apply:

-Women who are breast-feeding or planning to become pregnant during the study

A participant has received any of the following substances:

  • Receipt of any licensed influenza vaccine or lab-confirmed influenza infection within 6 months prior to enrollment.
  • Plan to or is required to receive a licensed influenza vaccine during study participation
  • within 4 weeks prior to enrollment
  • Inactivated vaccines within 2 weeks prior to enrollment
  • mRNA vaccines within 4 weeks prior to enrollment
  • Receipt of the HA ferritin influenza vaccine VRC-FLUNPF081-00-VP alone or in prime-boost regimens with VRC-FLUDNA082-00-VP (HA-F A/Sing, DNA A/Sing, VRC 316).
  • Receipt of the mosaic quadrivalent influenza vaccine VRC-FLUMOS0111-00-VP (FluMos-v1, VRC 325)
  • Receipt of the mosaic hexavalent influenza vaccine VRC-FLUMOS0116-00-VP (FluMos-v2, VRC 326)
  • More than 10 days of systemic medications or cytotoxic medications within the 4 weeks prior to enrollment or any within the 14 days prior to enrollment
  • Blood products within 16 weeks prior to enrollment
  • research agents within 4 weeks prior to enrollment or planning to receive investigational products while on the study
  • Current allergy treatment with allergen immunotherapy with antigen injections, unless on maintenance schedule
  • Current anti-TB prophylaxis or therapy

Participant has a history of any of the following conditions:

  • Serious reactions to vaccines that preclude receipt of the study vaccinations as determined by the PI or designee
  • Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema
  • Asthma that is not well controlled
  • Diabetes mellitus (type I or II), except for gestational diabetes
  • Thyroid disease that is not well controlled
  • Idiopathic urticaria within the past year
  • Immune-mediated diseases, such as or autoinflammatory diseases, or immunodeficiencies
  • Hypertension that is not well controlled
  • Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  • that is active or history of malignancy that is likely to recur during the period of the study
  • Seizure disorder other than 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years
  • Asplenia, functional asplenia or any condition resulting in the absence or removal of the spleen
  • Guillain-Barr(SqrRoot)(Copyright) Syndrome
  • Any medical, social condition, occupational reason, or other reason that, in the judgment of the PI or designee, is a to protocol participation or impairs a participant's ability to give , including but not limited to clinically significant forms of infectious diseases, drug or alcohol abuse, autoimmune diseases, psychiatric disorders, or heart disease.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Group 1

    60 mcg of SteMos1 on Day 0 and Week 16

    Biological: VRC-FLUMOS0122-00-VP

  • Experimental
    Group 2

    180 mcg of SteMos1 on Day 0 and Week 16

    Biological: VRC-FLUMOS0122-00-VP

  • Experimental
    Group 3

    60 mcg of SteMos1 + 0.5 ml of ALFQ on Day 0 and Week 16

    Biological: VRC-FLUMOS0122-00-VP · Other: ALFQ

  • Experimental
    Group 4

    180 mcg of SteMos1 + 0.5 ml of ALFQ on Day 0 and Week 16

    Biological: VRC-FLUMOS0122-00-VP · Other: ALFQ

  • Experimental
    Group 5- optional

    SteMos1 \[dose TBD based on interim analysis of data from Groups 3-4\] + 0.5 ml of ALFQ on Day 0 and Week 16

    Biological: VRC-FLUMOS0122-00-VP · Other: ALFQ

Interventions

  • BiologicalVRC-FLUMOS0122-00-VP

    The VRC-FLUMOS0122-00-VP (SteMos1) is composed of de novo engineered pentamer assembled with de novo engineered trimeric domains to an icosahedral core, projecting 20 HA stabilized stem trimers from four influenza A strains representing both Group 1 (H2, H5) and Group 2 (H7, H10) viruses.

  • OtherALFQ

    The ALFQ drug product is a sterile suspension that contains 240 mcg of monophosphoryl 3-deacyl Lipid A (3D-PHAD) and 120 mcg QS-21

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of 180 mg VRCFLUMOS0122-00-VP (SteMos1) vaccine with ALFQ adjuvant administered as a 2-dose regimen

    Assessed by:-Frequency and severity of solicited local reactogenicity symptoms reported for 7 days following each injection, through resolution of symptoms.-Frequency and severity of solicited systemic reactogenicity symptoms reported for 7 days following each injection, through the resolution of symptoms.-Frequency and grade of any unsolicited AEs, including abnormal safety laboratory measures, during the 28-day follow-up period post each product administration.-Frequency and grade of unsolicited AEs assessed as related to the product during the 28-day follow-up period after each product administration, -Frequency of adverse events leading to participant s withdrawal at any time throughout the study. -Frequency of SAEs, AESI, MAAEs and new chronic medical conditions that require ongoing medical management at any time throughout the study.

    Time frame: Though 52 weeks after the second vaccine administration

  2. Safety and tolerability of 60 mg VRCFLUMOS0122-00-VP (SteMos1) vaccine with ALFQ adjuvant administered as a 2-dose regimen

    Assessed by:-Frequency and severity of solicited local reactogenicity symptoms reported for 7 days following each injection, through resolution of symptoms.-Frequency and severity of solicited systemic reactogenicity symptoms reported for 7 days following each injection, through the resolution of symptoms.-Frequency and grade of any unsolicited AEs, including abnormal safety laboratory measures, during the 28-day follow-up period post each product administration.-Frequency and grade of unsolicited AEs assessed as related to the product during the 28-day follow-up period after each product administration, -Frequency of adverse events leading to participant s withdrawal at any time throughout the study. -Frequency of SAEs, AESI, MAAEs and new chronic medical conditions that require ongoing medical management at any time throughout the study.

    Time frame: Though 52 weeks after the second vaccine administration

  3. Safety and tolerability of 180 mg VRCFLUMOS0122-00-VP (SteMos1) vaccine without ALFQ adjuvant administered as a 2-dose regimen

    Assessed by:-Frequency and severity of solicited local reactogenicity symptoms reported for 7 days following each injection, through resolution of symptoms.-Frequency and severity of solicited systemic reactogenicity symptoms reported for 7 days following each injection, through the resolution of symptoms.-Frequency and grade of any unsolicited AEs, including abnormal safety laboratory measures, during the 28-day follow-up period post each product administration.-Frequency and grade of unsolicited AEs assessed as related to the product during the 28-day follow-up period after each product administration, -Frequency of adverse events leading to participant s withdrawal at any time throughout the study. -Frequency of SAEs, AESI, MAAEs and new chronic medical conditions that require ongoing medical management at any time throughout the study.

    Time frame: Though 52 weeks after the second vaccine administration

  4. Safety and tolerability of 60 mg VRCFLUMOS0122-00-VP (SteMos1) vaccine without ALFQ adjuvant administered as a 2-dose regimen

    Assessed by:-Frequency and severity of solicited local reactogenicity symptoms reported for 7 days following each injection, through resolution of symptoms.-Frequency and severity of solicited systemic reactogenicity symptoms reported for 7 days following each injection, through the resolution of symptoms.-Frequency and grade of any unsolicited AEs, including abnormal safety laboratory measures, during the 28-day follow-up period post each product administration.-Frequency and grade of unsolicited AEs assessed as related to the product during the 28-day follow-up period after each product administration, -Frequency of adverse events leading to participant s withdrawal at any time throughout the study. -Frequency of SAEs, AESI, MAAEs and new chronic medical conditions that require ongoing medical management at any time throughout the study.

    Time frame: Though 52 weeks after the second vaccine administration

Secondary outcomes

  1. Antibody responses to 180 mcg VRCFLUMOS0122-00-VP (SteMos1) vaccine administered with ALFQ as a 2-dose regimen

    Binding antibody responses to VRCFLUMOS0122-00-VP (SteMos1) with and without ALFQ adjuvant at Week 2 after the first vaccination and at Week 18, 2 weeks after the second vaccination.

    Time frame: Two weeks after each injection

  2. Antibody responses to 60 mcg VRCFLUMOS0122-00-VP (SteMos1) vaccine administered with ALFQ as a 2-dose regimen

    Binding antibody responses to VRCFLUMOS0122-00-VP (SteMos1) with and without ALFQ adjuvant at Week 2 after the first vaccination and at Week 18, 2 weeks after the second vaccination.

    Time frame: Two weeks after each injection

  3. Antibody responses to 180 mcg VRCFLUMOS0122-00-VP (SteMos1) administered without ALFQ as a 2-dose regimen

    Binding antibody responses to VRCFLUMOS0122-00-VP (SteMos1) with and without ALFQ adjuvant at Week 2 after the first vaccination and at Week 18, 2 weeks after the second vaccination.

    Time frame: Two weeks after each injection

  4. Antibody responses to 60 mg VRCFLUMOS0122-00-VP (SteMos1) vaccine administered without ALFQ as a 2-dose regimen

    Binding antibody responses to VRCFLUMOS0122-00-VP (SteMos1) with and without ALFQ adjuvant at Week 2 after the first vaccination and at Week 18, 2 weeks after the second vaccination.

    Time frame: Two weeks after each injection

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
08

References and documents

Publications

  • Ober Shepherd BL, Scott PT, Hutter JN, Lee C, McCauley MD, Guzman I, Bryant C, McGuire S, Kennedy J, Chen WH, Hajduczki A, Mdluli T, Valencia-Ruiz A, Amare MF, Matyas GR, Rao M, Rolland M, Mascola JR, De Rosa SC, McElrath MJ, Montefiori DC, Serebryannyy L, McDermott AB, Peel SA, Collins ND, Joyce MG, Robb ML, Michael NL, Vasan S, Modjarrad K; EID-030 Study Group. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial. Lancet Microbe. 2024 Jun;5(6):e581-e593. doi: 10.1016/S2666-5247(23)00410-X. Epub 2024 May 15. PubMed 38761816 ↗
  • Boyoglu-Barnum S, Ellis D, Gillespie RA, Hutchinson GB, Park YJ, Moin SM, Acton OJ, Ravichandran R, Murphy M, Pettie D, Matheson N, Carter L, Creanga A, Watson MJ, Kephart S, Ataca S, Vaile JR, Ueda G, Crank MC, Stewart L, Lee KK, Guttman M, Baker D, Mascola JR, Veesler D, Graham BS, King NP, Kanekiyo M. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature. 2021 Apr;592(7855):623-628. doi: 10.1038/s41586-021-03365-x. Epub 2021 Mar 24. PubMed 33762730 ↗
  • Widge AT, Hofstetter AR, Houser KV, Awan SF, Chen GL, Burgos Florez MC, Berkowitz NM, Mendoza F, Hendel CS, Holman LA, Gordon IJ, Apte P, Liang CJ, Gaudinski MR, Coates EE, Strom L, Wycuff D, Vazquez S, Stein JA, Gall JG, Adams WC, Carlton K, Gillespie RA, Creanga A, Crank MC, Andrews SF, Castro M, Serebryannyy LA, Narpala SR, Hatcher C, Lin BC, O'Connell S, Freyn AW, Rosado VC, Nachbagauer R, Palese P, Kanekiyo M, McDermott AB, Koup RA, Dropulic LK, Graham BS, Mascola JR, Ledgerwood JE; VRC 321 study team. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci Transl Med. 2023 Apr 19;15(692):eade4790. doi: 10.1126/scitranslmed.ade4790. Epub 2023 Apr 19. PubMed 37075129 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 23 months after the start.

Of 54 non-industry phase 1 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 23 months is above that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 8, 2025
StartActual
Aug 27, 2025
Primary completionEst.
Aug 18, 2027
CompletionEst.
Aug 18, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Received at least one licensed influenza vaccine from the 2020-2021 influenza season through the 2024-2025 influenza seasonNow Received at least one licensed influenza vaccine within the 5 years prior to enrollment
  • EditedAvailable for clinic visits for 68 weeks after the first dose, including through the 2025-2026 influenza season
Exclusion criteria
  • EditedPlan to or areis required to receive the 2025-2026 or 2026-2027a licensed influenza vaccinesvaccine during study participation
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Received at least one licensed influenza vaccine from the 2020-2021 influenza season through the 2024-2025 influenza seasonNow Received at least one licensed influenza vaccine within the 5 years prior to enrollment
    • EditedAvailable for clinic visits for 68 weeks after the first dose, including through the 2025-2026 influenza season
    Exclusion criteria
    • EditedPlan to or areis required to receive the 2025-2026 or 2026-2027a licensed influenza vaccinesvaccine during study participation
    + 1 other change: description
  2. Oct 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07111078
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Aug 27, 2025
Primary completion
Aug 18, 2027 (estimated)
Completion
Aug 18, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

VRC Clinic
Contact
vaccines@nih.gov
(301) 451-8715
Lesia K Dropulic, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion